RxDoctor Payments DataLook up a doctor →

Steven Margolis, MD

Family Medicine · Sterling Heights, MINPI 1619931268

Payments from drug & device makers

$90,501in general payments, 2019–2025

Across 691 payments — averaging $130.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$32K
  • Amgen$16K
  • Kowa Pharmaceuticals America, Inc.$14K
  • Madrigal Pharmaceuticals$9K
  • Esperion Therapeutics, Inc.$8K
  • Medicure Pharma Inc.$2K
  • plus $10K from 35 others

What the payments were for

  • Consulting fees$7001%
  • Speaking & faculty fees$63,03070%
  • Travel & lodging$9,24410%
  • Food & beverage$16,84119%
  • Education$600%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$90,501 in reported general payments places this provider in the 95th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$89,358
Medicare patients
154
Services billed
918

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide22$32,753
MounjaroTirzepatide15$19,684
Repatha SureclickEvolocumab19$19,071
JardianceEmpagliflozin18$17,086
Ezetimibe119$2,661
Rosuvastatin Calcium84$1,871
Atorvastatin Calcium113$1,586
Telmisartan23$1,576
Levothyroxine Sodium117$1,164
Metoprolol Succinate62$1,139
Nebivolol Hcl15$1,064
Niacin ErNiacin11$1,062
Ibandronate Sodium24$884
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen29$769
Testosterone Cypionate25$735

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,096$32,75322 claims
Lilly USA, LLCMounjaro$1,437$19,68415 claims
Boehringer IngelheimJardiance$37$17,08618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Sterling Heights

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →